Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07203742 | The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment | recruiting | N/A | 60 | Ege UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 |
| clinicaltrials |
| NCT04645199 | National Longitudinal Cohort of Hematological Diseases(NICHE) | recruiting | — | 2,300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07328191 | Quality of Life-Guided Transfusion in Refractory MDS or AML(Q-TRANS) | recruiting | N/A | 52 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06950034 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | recruiting | Phase 1 | 105 | Solu Therapeutics, IncINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07130695 | Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation | recruiting | Phase 1 | 15 | Virginia Commonwealth UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07148180 | A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | recruiting | Phase 1 / Phase 2 | 31 | Jacqueline Garcia, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07172204 | Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML(CHANCE) | recruiting | Phase 2 | 25 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07250217 | Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients(LAMME) | recruiting | N/A | 30 | Groupe Hospitalier de la Region de Mulhouse et Sud AlsaceOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07259707 | Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML(GANCE) | recruiting | Phase 2 | 25 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05917405 | Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT(FLUCLORIC) | recruiting | Phase 2 | 302 | Nantes University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07321626 | Romiplostim N01 for Platelet Recovery After Haploidentical HSCT | recruiting | Phase 1 | 130 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies | recruiting | Phase 2 / Phase 3 | 64 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT06326463 | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | recruiting | Phase 1 | 18 | St. Jude Children's Research HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | recruiting | — | 5,000 | MPN Research FoundationOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | recruiting | Phase 1 | 60 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347171 | A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies | recruiting | Phase 1 | 45 | Cullgen (Shanghai),IncOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05287568 | CC-486 and Venetoclax for Acute Myeloid Leukemia | recruiting | Phase 1 | 35 | University of Colorado, DenverOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06429449 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07119970 | Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)(AVATARE) | recruiting | N/A | 300 | University Hospital, BordeauxOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05317403 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | recruiting | Phase 1 | 40 | Medical College of WisconsinOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)(CARDINAL) | recruiting | Phase 1 / Phase 2 | 180 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 9 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06743035 | Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly(ROPE) | recruiting | — | 200 | iOMEDICO AGINDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04644211 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04872478 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | recruiting | Phase 1 | 50 | Meryx, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05342584 | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS(Venetoclax AML) | recruiting | Phase 1 | 99 | Montefiore Medical CenterOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05597306 | Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia(VenBom) | recruiting | Phase 1 | 18 | Terrence J Bradley, MDOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT01252485 | Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project(AMLSG BiO) | recruiting | — | 50,000 | University of UlmOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT05184842 | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | recruiting | Phase 2 | 91 | Montefiore Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06452732 | Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML | recruiting | — | 283 | Peking University People's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03326310 | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | recruiting | Phase 1 | 18 | University of ChicagoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05657639 | CAV Regimen for R/R AML | recruiting | Phase 2 | 68 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07304232 | Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML(CM-AML-001) | recruiting | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05105152 | PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML | recruiting | Phase 1 | 18 | Seattle Children's HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06541249 | MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial(TREATMORE) | recruiting | Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06552416 | Safety of MT-401-OTS in Patients With Relapsed AML or MDS(RAPID) | recruiting | Phase 1 | 40 | Marker Therapeutics, Inc.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07121140 | Home Blood Transfusions | recruiting | N/A | 30 | Thomas Jefferson UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07153068 | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06680752 | Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS | recruiting | Phase 1 / Phase 2 | 49 | ARCE Therapeutics, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03828773 | PTX3-targeted Antifungal Prophylaxis(PTX3AML) | recruiting | N/A | 410 | Bochud Pierre-YvesOTHER | 3 | Dec 9, 2025 | clinicaltrials |
| NCT06782971 | Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX(COSMOS-Avatar) | recruiting | — | 25 | Clinical Hub for Interventional Research (CHOIR)OTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05024552 | Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | recruiting | Phase 1 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06649227 | Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19(CARLA-M19) | recruiting | Phase 1 | 5 | University Hospital, LilleOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03300492 | Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS | recruiting | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05194397 | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors(IAMFIT) | recruiting | Phase 2 | 80 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263906 | Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia | recruiting | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07256210 | Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06377579 | OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia | recruiting | — | 250 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | recruiting | Phase 3 | 486 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Nov 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2026source: clinicaltrials